Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)

项目摘要/摘要 阿片类药物使用障碍(OUD)是一种慢性、反复发作的疾病，如果不治疗，会造成严重的 和持续的公共卫生威胁。OUD与严重的生理和心理障碍有关 心理健康，包括死亡率上升和紧急医疗服务利用率高以及 增加丙型肝炎和艾滋病毒感染以及新生儿禁欲综合征(NAS)的风险。OUD也是 与更多的司法和儿童福利系统参与有关。目前，经验性的 支持的行为干预治疗ODS是有限的，其中大部分不能量身定做 (定制)以满足个人客户的独特需求。因此，患有这种疾病的人的复发率 ODS仍然居高不下。 虚拟现实线索曝光(VRCE)在解决物质渴望方面显示出相当大的前景，这是 OUD最突出的组成部分。通过反复接触物质使用线索在受控的 虚拟环境，随着时间的推移，这些虚拟暴露会削弱物质使用线索之间的关系 和渴望，潜在地导致物质使用的减少和物质复发的可能性降低。 遗憾的是，目前可用的商用VR产品缺乏轻松和重复使用的必要能力 更新暴露环境以引入新颖性或纳入新的或不断发展的物质使用线索。这 随着时间的推移，限制会导致用户参与度降低，可能会导致用户脱离参与度和过早使用 终止治疗。 通过R41项目《临床物质使用模块化自适应虚拟现实干预》 无序(MAVRICS)“，这项研究旨在改进目前可用的商业虚拟现实(VR) 旨在通过开发新的基于订阅的软件产品来解决物质滥用问题的产品 (Helix)，支持基于虚拟现实的线索曝光(VRCE)环境的持续定制 导致了针对物质渴望的量身定做的干预。通过i-Corp计划，广告 将进一步探索Helix的潜力，并提出与Helix不同商业方面有关的五个假设 将通过对OUD治疗领域的潜在客户和专家的一系列采访进行测试。

PROJECT SUMMARY/ABSTRACT Opioid Use Disorder (OUD) is a chronic, recurring condition that if left untreated, poses a significant and ongoing public health threat. OUD is associated with significant impairments in physical and psychological health including increased mortality and high utilization of emergency medical care as well as increased risk of Hepatitis C and HIV infection and Neonatal Abstinence Syndrome (NAS). OUD is also associated with increased justice and child welfare systems involvement. Currently, the number of empirically supported behavioral interventions for the treatment of OUDs is limited, the majority of which cannot be tailored (customized) to meet the unique needs of the individual client. As such, the relapse rate for individuals with OUDs remains high. Virtual reality cue exposure (VRCE) has shown considerable promise in addressing substance craving, one of the most salient components of OUD. Through repeated exposure to substance use cues within a controlled virtual environment, over time these virtual exposures weaken the relationship between substance use cues and craving, potentially leading to decreased substance use and lower probability of substance relapse. Unfortunately, currently available commercial VR products lack the essential ability to easily and repeatedly update exposure environments to introduce novelty or incorporate new or evolving substance use cues. This limitation results in less user engagement over time, potentially leading to user disengagement and premature treatment termination. Through the R41 project titled “Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)”, the research aims to improve upon currently available commercial virtual reality (VR) products designed to address substance misuse by developing a novel subscription-based software product (Helix) that supports ongoing customization of virtual reality-based cue exposure (VRCE) environments resulting in a tailored intervention addressing substance craving. Through the I-Corp program, the commercial potential for Helix will be further explored and five hypotheses pertaining to various commercial aspect of Helix will be tested through a series of interviews with potential customers and experts in the field of OUD treatment.